ISSN |
1949-8470 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Observational Study |
Article Title |
Comparisons between glucose analogue 2-deoxy-2-(18F)fluoro-D-glucose and 18F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions
|
Manuscript Source |
Invited Manuscript |
All Author List |
Selene Capitanio, Francesca Bongioanni, Arnoldo Piccardo, Claudio Campus, Roberta Gonella, Lucia Tixi, Mehrdad Naseri, Michele Pennone, Vania Altrinetti, Ambra Buschiazzo, Irene Bossert, Francesco Fiz, Andrea Bruno, Andrea DeCensi, Gianmario Sambuceti and Silvia Morbelli |
Funding Agency and Grant Number |
|
Corresponding Author |
Silvia Morbelli, Full Staff Nuclear Medicine Physician, Nuclear Medicine, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, L.go R. Benzi 10, 16132 Genova,
Italy. silviadaniela.morbelli@hsanmartino.it
|
Key Words |
18F-sodium positron emission tomography/computed tomography; Breast cancer; Bone lesion; 2-deoxy-2-(18F)fluoro-D-glucose |
Core Tip |
18F-fluorodeoxyglucose (18F-FDG) and 18F-sodium positron (18F-NaF) positron emission tomography/computed tomography (PET/CT) is undoubtedly an accurate and validated imaging tool in the general population of breast cancer patients for the detection of bone metastasis in most cases. However, thanks to its extremely high sensitivity, 18F-NaF PET/CT could have an adjunctive value in selected patients, significantly impacting their management (i.e., small CT-evident sclerotic lesions, high clinical suspicious of relapse, and negative 18F-FDG PET and conventional imaging). This sensitivity might be particularly relevant for patients who are candidates for surgery or radiotherapy.
|
Publish Date |
2016-02-26 17:04 |
Citation |
Capitanio S, Bongioanni F, Piccardo A, Campus C, Gonella R, Tixi L, Naseri M, Pennone M, Altrinetti V, Buschiazzo A, Bossert I, Fiz F, Bruno A, DeCensi A, Sambuceti G, Morbelli S. Comparisons between glucose analogue 2-deoxy-2-(18F)fluoro-D-glucose and 18F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions. World J Radiol 2016; 8(2): 200-209 |
URL |
http://www.wjgnet.com/1949-8470/full/v8/i2/200.htm |
DOI |
http://dx.doi.org/10.4329/wjr.v8.i2.200 |